



The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee July 2023 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Abemaciclib	Verzenio	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
2	Albutrepenonacog alfa	Idelvion	Cardiovascular system	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
3	Anifrolumab	Saphnelo	Musculoskeletal and joint disease	Pending	Pending further information
4	Avalglucosidase alfa	Nexviazyme	Nutrition and blood	Approved	
5	Darolutamide	Nubeqa	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
6	Dupilumab	Dupixent	Skin	Approved	
7	Faricimab	Vabysmo	Eye	Approved	
8	Febuxostat	Feburic	Musculoskeletal and joint disease	Approved	
9	Finerenone	Kerendia	Cardiovascular system	Approved	
10	Infliximab	Remsima	Gastro-intestinal system	Approved	
11	Insulin glargine	Toujeo	Endocrine system	Pending	Pending further information
12	Lenvatinib / Pembrolizumab	Lenvima / Keytruda	Malignant disease and immunosuppression	Approved	
13	Luspatercept	Reblozyl	Nutrition and blood	Approved	
14	Paclitaxel albumin	Abraxane	Malignant disease and immunosuppression	Approved	
15	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
16	Ripretinib	Qinlock	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
17	Risankizumab	Skyrizi	Musculoskeletal and joint disease	Approved	
18	Ruxolitinib	Jakavi	Malignant disease and immunosuppression	Approved	
19	Sotorasib	Lumakras	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
20	Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Pending	Pending further information
21	Trastuzumab	Herzuma	Malignant disease and immunosuppression	Pending	Pending further information
22	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Approved	
23	Tucatinib	Tukysa	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
24	Zanubrutinib	Brukinsa	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.